Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Consensus Rating of “Moderate Buy” by Analysts

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) has been given a consensus rating of “Moderate Buy” by the five analysts that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $4.50.

Several research analysts have recently commented on the company. Canaccord Genuity Group reduced their price target on Tenaya Therapeutics from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. HC Wainwright reduced their target price on shares of Tenaya Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a report on Friday, December 12th. Chardan Capital lowered their price target on shares of Tenaya Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, December 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tenaya Therapeutics in a research report on Wednesday, October 8th. Finally, Morgan Stanley set a $2.00 target price on shares of Tenaya Therapeutics in a research report on Thursday, January 8th.

Tenaya Therapeutics Stock Performance

Shares of TNYA opened at $0.75 on Friday. The company has a 50 day moving average price of $0.97 and a 200-day moving average price of $1.14. Tenaya Therapeutics has a fifty-two week low of $0.36 and a fifty-two week high of $2.35. The stock has a market capitalization of $125.53 million, a PE ratio of -0.97 and a beta of 3.18.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03. Equities research analysts forecast that Tenaya Therapeutics will post -1.35 EPS for the current year.

Institutional Trading of Tenaya Therapeutics

Institutional investors have recently made changes to their positions in the business. Mirador Capital Partners LP grew its stake in Tenaya Therapeutics by 2,378.8% during the 4th quarter. Mirador Capital Partners LP now owns 582,524 shares of the company’s stock worth $414,000 after buying an additional 559,024 shares during the last quarter. Scientech Research LLC purchased a new stake in shares of Tenaya Therapeutics during the third quarter worth about $27,000. Millennium Management LLC increased its holdings in shares of Tenaya Therapeutics by 561.7% during the third quarter. Millennium Management LLC now owns 4,504,592 shares of the company’s stock valued at $7,297,000 after acquiring an additional 3,823,848 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in shares of Tenaya Therapeutics in the 3rd quarter valued at approximately $755,000. Finally, Two Sigma Investments LP raised its position in shares of Tenaya Therapeutics by 91.8% in the 3rd quarter. Two Sigma Investments LP now owns 910,568 shares of the company’s stock valued at $1,475,000 after purchasing an additional 435,781 shares during the last quarter. Institutional investors and hedge funds own 90.54% of the company’s stock.

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.